• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center
 

Member Resources

Pipelines in Oncology

November 11, 2010 - Seattle Genetics

http://www.seagen.com

Jonathan Drachman, Senior Vice President, Research and Translational Medicine

Presentation on:

"Seattle Genetics: Developing Empowered Antibody Therapies for Cancer"


October 26, 2010 - VBL Therapeutics

http://vblrx.com

Prof. Dror Harats - CEO
Yael Cohen - Vice President for Clinical Development

Programs Presented:

  • VB-111, a Tissue and Condition Specific Vascular Disruptive Anti-Angiogenic Agent, Based on Novel Vascular Targeting System, VTS: pre-clinical and clinical development


October 6, 2010 - Allos Therapeutics

http://www.allos.com

Steven Stein, MD; Vice President, Global Oncology Clinical Development
Peter Lebowitz, MD; Vice President, Drug Discovery
Carl Barrett; VP & Global Head Oncology Biomarkers & Clinical Imaging

1:1 Meetings only


 

June 24, 2010 - Peregrine Pharmaceuticals

http://www.peregrineinc.com

Philip Thorpe - Professor of Pharacology and Serena Simmons Distinguished Chair, University of Texas Southwestern Medical Center
Joseph Shan - Vice President, Clinical and Regularory Affairs, Peregrine Pharmaceuticals
Marvin Garovoy - Head, Clinical Science, Peregrine Pharmaceuticals

Presentation on:

  • Bavituximab: An anti-phosphatidylserine targeting antibody that damages tumore blood vessels and induces tumor immunity.


May 18, 2010 - Fusion Antibodies/Fusion Therapeutics

http://www.fusionantibodies.com

Shane Olwill, Phd; Research Director

Presentation on:

  • Targeting Cathepsin S for the treatment of colorectal cancer


 

April 11, 2010 - ImmuneXcite

http://www.immunexcite.com/

Yaniv Bejerano - President and CEO
Ifat Rubin-Bejerano - CSO

Presentation on:

  • mAbXicte Platform Technology coats cancer celles with fungal polysacharide and makes them a target for neutrophils.


April 29, 2010 - Merck

http://www.merck.com

Gary Gilliland, MD - Senior Vice President of Merck Reseearch Laboratoeies (MRL) and Oncology Franchise Head

Presentation on:

  • Overview of the Merch-Schering Pipeline


April 16, 2010 - Halozyme

http://www.halozyme.com

H. Michael Shepard, PhD - Vice President of Discovery Research

Presentation on:

Remodeling the tumor stroma as a new modality in cancer research


March 18, 2010 - Macrogenics

http://www.macrogenics.com

Scott Koenig, MD, PhD - President and CEO
Paul Moore, PhD - Senior Director, Immunology and Cell Biology

Presentation on:

Therapeutic Antibody based strategies to target cancer through recruitment of immuned effector populations.


March 3, 2010 - Onyx Pharmaceuticals

http://www.onyx-pharm.com

Joe Leveque, MD - VP for Medical Affairs
Michael Kaufmann, MD - Chief Medical Officer
Nathalie Locker, PhD - Senior Director, Clinical Science
Christopher Kirk, PhD - Director, Preclinical Research
Richard Bryce, MD - Senior Director, Clinical Development
Dale Pike - Medical Science Liaison

Presentation on:

  • Sorafenib
  • ONX 0801 targeted antifolate
  • ONX 0803 and ONX 0805 JAK inhibitors
  • ONX 0912 and ONX 0914 Proteasome Inhibitors


February 3, 2010 - Cell Therapeutics

http://www.celltherapeutics.com

Monica L'Tainen - Medical Science Liaison
Kris Kanellopoulos - Associate Director MSLs Medical Affairs

Presentation on:

  • Pixatrone
  • Brostallicin
  • Opaxio


January 21, 2010 - Eisai Oncology

http://www.eisai.com

John Wang, PhD Director, Oncology Product Creation Unit
Kenichi Nomoto, PhD - Senior Director, Oncology Product Creation Unit
Mary Woodall-Jappe, PhD - Principle Scientist, Oncology Product Creation Unit
Nanding Zhao, PhD - Senior Research Investigator
Eva Gallagher - Medical Science Liaision

Presentation on:

  • E7080 - multiple kinase inhibitor
  • E7974 - Hemiasterlin analog
  • E7389 - Eribulin mesylate


January 13, 2010 - Micromet

http://www.micromet.de

Patrick Baeuerle, PhD Senior Vice President and CSO
Markus Muenz, PhD Director, EpCAM Program

Presentation on:

  • Blinatumomab (MT103)
  • Adecatumumab (MT102)
  • MT293 (TRC093)
  • MT110 for solid tumors
  • MT 111
  • MT 228 (MORab-028)